http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
GO-17 : Makorin Ring Finger Protein 1 (MKRN1) as an adjunct marker in liquid-based cervical cytology
( Ji Yun Lee ),( Hyeong Ju Kim ),( Jinkyoung Kong ),( Ji Hee Choi ),( Geum Seon Sohn ),( Hanbyoul Cho ),( Eun Ji Nam ),( Sang Wun Kim ),( Doo Byung Chay ),( Sunghoon Kim ),( Young Tae Kim ),( Jae Hoon 대한산부인과학회 2014 대한산부인과학회 학술대회 Vol.100 No.-
목적: The aim of the study was to test the ability of MKRN1 to detect cervical lesion in a screening setting and its use as a surrogate marker of HPV infection. 방법: We conducted PROspective specimen collection and retrospective Blinded Evaluation (PROBE) study. Liquid-based cytology samples were collected from 187 women. A cell block was prepared from residual cervical cytology specimen for immunocytochemistry of MKRN1 and P16 INK4a.Liquid-based cervical cytology, MKRN1, P16 INK4a, P21, P57, KI-67 immunostaining on cell block sections, HPV hybrid capture and real time Polymerase chain reaction (PCR) were performed and analyzed with pathologic results.Clinical performances [sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV)] were calculated for all women and subgroup analysis was performed for patients with ASCUS or LSIL. 결과: MKRN1 positivity increased with histologic severity, from 32.4% in CIN1, 60.0% in CIN2, 80.0% in CIN3 to 92.3% in invasive cancer. The sensitivity, specificity, PPV and NPV of MKRN1 to detect CIN2+ was 73.8%, 76.8% 75.6%, and 75.0%, respectively. However, liquid-based cytology showed poorer clinical performance than MKRN1 immunostaining (61.3%, 69.5%, 66.2% and 64.8%, respectively) and HPV testing had lower specificity than MKRN1 (67.7%). When combining two screening tests, MKRN1 + HPV showed the highest sensitivity, specificity, PPV and NPV (71.8%, 85.5%, 82.3%, 76.5%, respectively), while there were no significant differences between cytology + HPV (60.6%, 81.8%, 75.4%, 69.2%) and cytology + MKRN1 (58.8%, 84.1%, 78.3%, 67.7%) in all aspects. In cases of ASCUS/LSIL, MKRN1 + HPV (100%, 72.7%, 73.9%, 100%, respectively) showed the best clinical performances followed by MKRN1 + cervical cytology (100%, 50.0%, 60.7%, 100%, respectively). 결론: MKRN1 was more sensitive and specific than liquid-based cytology, and it was more specific than HPV test. Our study showed that MKRN1 + HPV has the highest sensitivity and specificity when combining two diagnostic tests. As part of screening procedure, MKRN1 could be used as a satisfactory biomarker for the primary screening of cervical cytology.
Changes in Respiratory Virus Infection Trends during the COVID-19 Pandemic in South Korea
( Ji Young Park ),( Ji Young Park ),( Joo-hee Kim ),( Sunghoon Park ),( Yong Il Hwang ),( Seung Hun Jang ),( Yong Kyun Kim ),( Ki-suck Jung ) 대한결핵 및 호흡기학회 2021 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.129 No.-
Background Studies on the effectiveness of public health measures to prevent respiratory virus transmission in real-world settings are lacking. We investigated the effectiveness of universal mask use and adherence to other personal preventive measures on the changing viral respiratory infection patterns during the coronavirus disease 2019 (COVID-19) pandemic. Methods Data were extracted from the South Korean National Respiratory Virus Sentinel Surveillance System. During the COVID-19 pandemic, a cross-sectional survey on adherence to personal preventive measures was conducted. Additionally, the number of subway passengers was analyzed to estimate physical distancing compliance. Results During the pandemic, adherence to personal preventive measures significantly increased, particularly indoors and on public transportation. Respiratory virus trends were compared based on laboratory surveillance data of 47,675 patients with acute respiratory infections (2016-2020). The 2019-2020 influenza epidemic ended within three weeks, from the epidemic peak to the epidemic end, quickly ending the influenza season; with a 1.8-2.5-fold faster decline than in previous seasons. Previously, the overall respiratory virus positivity rate remained high after the influenza seasons had ended (47.7-69.9%). During the COVID-19 pandemic, this positive rate, 26.5%, was significantly lower than those in previous years. Hospital-based surveillance showed a decreased number of hospitalized patients with acute viral respiratory illnesses. Conclusion This study suggests that high compliance to the use of personal preventive measures in public might reduce the incidence of all respiratory virus infections and its hospitalization rates, with no additional quarantine, isolation, or contact screening.
( Ji Hyun Lee ),( Sang Hyun Cho ),( Kyung Jin Eoh ),( Jung-yun Lee ),( Eun Ji Nam ),( Sunghoon Kim ),( Sang Wun Kim ),( Young Tae Kim ) 대한산부인과학회 2020 Obstetrics & Gynecology Science Vol.63 No.3
Objective The umbilicus is a single, painful incisional site on the abdomen during trans-umbilical single-port access laparoscopic surgery. Previously, we found that periumbilical lidocaine could reduce postoperative pain. This study aimed to compare the efficacy of bupivacaine and lidocaine in reducing pain. Methods We performed a retrospective analysis in a study group (Bupivacaine group, 100 patients who received periumbilical infiltration of bupivacaine before their incisional site repair completion) and control group (Lidocaine group, 100 patients who received lidocaine at their incisional site repair completion). We compared postoperative pain based on the numerical rating scale (NRS) between propensity score-matched Bupivacaine-treated (n=50) and Lidocaine-treated (n=50) patients. Results The postoperative pain scores based on the NRS were not significantly different between the 2 groups until 12 hours post-operation. However, 24 hours post-operation, the Bupivacaine group showed significantly lower pain than the Lidocaine group (24 hours, 1.76±1.07 vs. 2.53±1.11 NRS, P<0.001; 48 hours, 0.84±0.85 vs. 2.16±0.85 NRS, P<0.001). Conclusion Periumbilical infiltration of bupivacaine has a longer acting efficacy on reducing postoperative surgical pain than that of lidocaine.
Robotic single-port transumbilical total hysterectomy: a pilot study
Nam, Eun Ji,Kim, Sang Wun,Lee, Maria,Yim, Ga Won,Paek, Ji Heum,Lee, San Hui,Kim, Sunghoon,Kim, Jae Hoon,Kim, Jae Wook,Kim, Young Tae Korean Society of Gynecologic Oncology and Colposc 2011 Journal of Gynecologic Oncology Vol.22 No.2
<P><B>Objective</B></P><P>To evaluate the feasibility of robotic single-port transumbilical total hysterectomy using a home-made surgical glove port system.</P><P><B>Methods</B></P><P>We retrospectively reviewed the medical records of patients who underwent robotic single-port transumbilical total hysterectomy between January 2010 and July 2010. All surgical procedures were performed through a single 3-4-cm umbilical incision, with a multi-channel system consisting of a wound retractor, a surgical glove, and two 10/12-mm and two 8 mm trocars.</P><P><B>Results</B></P><P>Seven patients were treated with robotic single-port transumbilical total hysterectomy. Procedures included total hysterectomy due to benign gynecological disease (n=5), extra-fascial hysterectomy due to carcinoma <I>in situ</I> of the cervix (n=1), and radical hysterectomy due to cervical cancer IB1 (n=1). The median total operative time was 109 minutes (range, 105 to 311 minutes), the median blood loss was 100 mL (range, 10 to 750 mL), and the median weight of the resected uteri was 200 g (range, 40 to 310 g). One benign case was converted to 3-port robotic surgery due to severe pelvic adhesions, and no post-operative complications occurred.</P><P><B>Conclusion</B></P><P>Robotic single-port transumbilical total hysterectomy is technically feasible in selected patients with gynecological disease. Robotics may enhance surgical skills during single-port transumbilical hysterectomy, especially in patients with gynecologic cancers.</P>
GO-24 : Forkhead box P1 (Foxp1) in cervical cancer
( Hyeong Ju Kim ),( Ji Yun Lee ),( Jinkyoung Kong ),( Ji Hee Choi ),( Geum Seon Sohn ),( Eun Ji Nam ),( Sang Wun Kim ),( Doo Byung Chay ),( Sunghoon Kim ),( Jae Hoon Kim ),( Young Tae Kim ),( Han Byou 대한산부인과학회 2014 대한산부인과학회 학술대회 Vol.100 No.-
목적: The forkhead box protein 1 (FOXP1) is considered as both a tumor suppressor candidate and a potential oncogene. Here, we investigated FOXP1 expression in cervical cancer, and the clinical significance of FOXP1 and it`s mechanism of action in cervical cancer. 방법: FOXP1`s functional role was investigated by employing lentiviral-mediated overexpression and knockdown in cervical cancer cell lines. Immunohistochemical staining for FOXP1 was performed on a cervical cancer tissue microarray consisting of 158 primary cervical cancers, 280 cervical intraepithelial neoplasias (CINs), and 378 matched normal tissues. 결과: FOXP1 overexpression promoted cell proliferation and tumorigenesis, whereas FOXP1 knockdown inhibited these properties in HeLa and CaSki cell lines. By immunohistochemical staining, FOXP1 expression increased during the normal to tumor transition of cervical carcinoma (p< 0.001), and this increased expression was significantly associated with tumor stage (p=0.009) and tumor grade (p< 0.001). In multivariate analysis, FOXP1+ (p=0.031) and tumor stage (p=0.032) were independent prognostic factors for overall survival. 결론: Taken together, our data indicate that FOXP1 has a crucial role in cervical cancer progression, and its overexpression is associated with poor prognosis, supporting that FOXP1 may be used as a promising novel target for therapeutic interventions.
Eoh, Kyung Jin,Kim, Ji Eun,Park, Hyung Seok,Lee, Seung-Tae,Park, Ji Soo,Han, Jung Woo,Lee, Jung-Yun,Kim, Sunghoon,Kim, Sang Wun,Kim, Jae Hoon,Kim, Young Tae,Nam, Eun Ji Korean Cancer Association 2018 Cancer Research and Treatment Vol.50 No.3
<P><B>Purpose</B></P><P>Next-generation sequencing (NGS) allows simultaneous sequencing of multiple cancer susceptibility genes and may represent a more efficient and less expensive approach than sequential testing. We assessed the frequency of germline mutations in individuals with epithelial ovarian cancer (EOC), using multi-gene panels and NGS.</P><P><B>Materials and Methods</B></P><P>Patients with EOC (n=117) with/without a family history of breast or ovarian cancer were recruited consecutively, from March 2016 toDecember 2016.GermlineDNAwas sequenced using 35-gene NGS panel, in order to identify mutations. Upon the detection of a genetic alteration using the panel, results were cross-validated using direct sequencing.</P><P><B>Results</B></P><P>Thirty-eight patients (32.5%) had 39 pathogenic or likely pathogenic mutations in eight genes, including <I>BRCA1</I> (n=21), <I>BRCA2</I> (n=10), <I>BRIP1</I> (n=1), <I>CHEK2</I> (n=2), <I>MSH2</I> (n=1), <I>POLE</I> (n=1), <I>RAD51C</I> (n=2), and <I>RAD51D</I> (n=2). Among 64 patients with a family history of cancer, 27 (42.2%) had 27 pathogenic or likely pathogenic mutations, and six (9.3%) had mutations in genes other than <I>BRCA1/2</I>, such as <I>CHECK2</I>, <I>MSH2</I>, <I>POLE</I>, and <I>RAD51C</I>. Fifty-five patients (47.0%) were identified to carry only variants of uncertain significance.</P><P><B>Conclusion</B></P><P>Using the multi-gene panel test, we found that, of all patients included in our study, 32.5% had germline cancer-predisposing mutations. NGS was confirmed to substantially improve the detection rates of a wide spectrum of mutations in EOC patients compared with those obtained with the <I>BRCA1/2</I> testing alone.</P>
GO-23 : Chemosensitivity testing based on gene expression profiling in patients with ovarian cancer
( Geum Seon Sohn ),( Hyeong Ju Kim ),( Ji Yun Lee ),( Jinkyoung Kong ),( Ji Hee Choi ),( Hanbyoul Cho ),( Eun Ji Nam ),( Sang Wun Kim ),( Sunghoon Kim ),( Jae Hoon Kim ),( Young Tae Kim ),( Doo Byung 대한산부인과학회 2014 대한산부인과학회 학술대회 Vol.100 No.-
목적: To evaluate the association between clinical response of treatment agents and results of chemosensitivity testing in ovarian cancer. 방법: Tissue was obtained from 21 ovarian cancer patients and gene expression was evaluated by quantitative real-time polymerase chain reaction (PCR). Selected gene panel with expression of specific genes in the pathways that are related to drug responses in ovarian cancer were analyzed( AKT, Aurora A, BCRP, CD31, ERCC1, GSTpi, HER2, MDR1, Mitosin, PI3 Kinase, RRM1, Survivin, TOP1, TOP2A, TS, VEGF, VEGFR2, XIAP, P73). Gene expression were matched with therapeutic agent including Platinum, Taxanes, Bevacizumab, Gemcitabine, Topoisomerase I Inhibitors, Topoisomerase II Inhibitors, Cyclophosphamide, Herceptin, and 5-fluorouracil for chemosensitivity. 결과: Chemosensitivity testing revealed sensitivity rate of 66%, 81%, 96%, 56% and 61% for Platinum, Taxanes, Topoisomerase I Inhibitors, Topoisomerase II Inhibitors, and Bevacizumab, respectively. Treatment response rate was 70% (Complete Response: 40%, Partial Response: 30%). Treatment response was not significantly increased in the platinum sensitive patients (p=0.613), and overall response rate did not significantly differ according to the chemosensitivity test. 결론: This study may provide useful information in optimizing individual chemotherapy in the treatment of ovarian cancer.
( Ji Young Park ),( Seung Hun Jang ),( Hwan Il Kim ),( Joo-hee Kim ),( Sunghoon Park ),( Yong Il Hwang ),( Ki- Suck Jung ),( Jinwon Seo ) 대한결핵 및 호흡기학회 2019 대한결핵 및 호흡기학회 추계학술대회 초록집 Vol.127 No.0
Background: EGFR T790M mutation is a robust biomarker for the efficacy of osimertinib. But its clinical efficacy is very limited in a part of patients with non-small cell lung cancer harboring EGFR T790M mutation, suggesting primary resistance. The purpose of this study was to discover clinical predictive factors for the efficacy of osimertinib. Methods: This retrospective study analyzed patients with stage IV, EGFR T790M positive lung adenocarcinoma given osimertinib as salvage treatment. Various baseline clinical factors were investigated according to favorable or unfavorable osimertinib efficacy group. Unfavorable efficacy (primary resistant) group was defined as progression- free survival (PFS) < 6 months with osimertinib. Results: Thirty patients were eligible for this analysis (19 of favorable and 11 of unfavorable efficacy group). PFS of favorable and unfavorable efficacy group with osimertinib were 9.9 months (95% CI 9.5- 10.3) and 3.3 months (95% CI 2.4-4.2), respectively (p<0.001). Response rate of osimertinib was 89.5% vs. 18.2% (p<0.001). The cases with age at the time of lung cancer diagnosis ≥ 60 years, baseline (before starting osimertinib) Neutrophil to Lymphocyte Ratio (NLR) ≤ 3.5, pre-osimertinib treatment with first-generation EGFR-TKI (gefintinib or erlotinib) rather than second-generation EGFR-TKI (afatinib) were more frequent in the favorable efficacy group (p=0.058, 0.058, and 0.088, respectively, chi-square test). Age at the time of lung cancer diagnosis, ECOG performance, baseline NLR, pre-osimertinib EGFR-TKI generation, and PFS with previous EGFR-TKI were revealed as potential predictive factors through Kaplan- Meier PFS estimation. Finally, Cox proportional hazard regression analysis confirmed age at the time of lung cancer diagnosis ≥ 60 years (HR 0.292, 95% CI 0.104-0.819, p=0.019) and baseline NLR ≤ 3.5 (HR 0.238, 95% CI 0.083-0.677, p=0.007) were good predictive factors for the efficacy of osimertinib. Conclusion: Relatively old age and low neutrophilic inflammation were associated with favorable efficacy of osimertinib.